CAS: 115-80-0; 1,1,1-Triethoxypropane

上下游产品

CAS号64-17-5 乙醇 | CAS号107-12-0 丙腈 | CAS号7647-01-0 盐酸 | CAS号21504-43-8 1,1-diethoxypro... | CAS号40546-35-8 丙亚胺酸盐酸乙酯 | CAS号104907-91-7 ethyl 5-(2-ethy... | CAS号53399-81-8 2-甲基-4-戊烯酸乙酯 | CAS号565-69-5 2-甲基-3-戊酮 | CAS号57610-38-5 2-乙基-1H-咪唑-4,5-二甲腈 | CAS号144485-92-7 2-ethyl-7-methy... | CAS号140910-77-6 8-chloro-3-ethy... | CAS号925-78-0 3-壬酮 | CAS号20514-29-8 2-乙基-5-甲基苯并噁唑 | CAS号204771-74-4 2-乙基-5-硝基苯并噁唑 | CAS号78-09-1 原碳酸四乙酯

6-Chloro-2-Hydrazino-3-Methoxyquinoxaline 反应生成原丙酸三乙酯
参考文献:Method Of Using [1,2,4]Triazolo[4,3-A]Quinoxaline-4-Amine Derivatives As
标题:Method Of Using [1,2,4]Triazolo[4,3-A]Quinoxaline-4-Amine Derivatives As
摘要:一系列新型[1,2,4]三唑并[4,3-A]喹喔啉-4-胺衍生物,其中胺基可选择地被较低的烷基,含有最多三个碳原子的苯基烷基或含有两至五个碳原子的烷酰基取代,或者胺基可选择地形成哌嗪环,喹喔啉环可选择地被氟,氯,溴或甲氧基取代,三唑环可选择地被较低的烷基,较低的全氟烷基或苯基取代.这些新型化合物可用于治疗与抑郁症状相关的症状.还公开了含有本发明新型化合物的药物组合物以及使用这些化合物治疗抑郁症和疲劳的方法.

专利信息

专利号:US-8115002-B2
优先权日:2006-09-20
标 题:Preparation of substituted morphinan-6-ones and salts and intermediates thereof
发明人：WANG PETER X; MOSER FRANK W; CANTRELL GARY L; GROTE CHRISTOPHER W
权利人:WANG PETER X; MOSER FRANK W; CANTRELL GARY L; GROTE CHRISTOPHER W; MALLINCKRODT LLC
摘要:The present invention is directed to processes for the synthesis of morphinan-6-ones and salts, intermediates, and analogs thereof.

专利号:US-7161024-B2
优先权日:2003-07-10
标题 :Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters
发明人：DRAPER RICHARD W
权利人:SCHERING CORP
摘要:In its several embodiments, this invention discloses a novel process to prepare the compounds of Formula 3: n nwherein R 1 is lower alkyl, and R 2 and R 3 can be the same or different, each being independently selected from the group consisting of alkyl, aryl and aralkyl; said process being carried out in a suitable solvent with at least one tert-amine carboxylate salt catalyst. The compounds of formula 3 are chemical intermediates useful for the synthesis of various heterocyclic compounds. These heterocyclic compounds are in turn useful precursors for diverse pharmaceutical, herbicidal and insecticidal agents. In particular, these intermediates are useful precursors to a variety of CCR5 inhibitors.

专利号:WO-2024220193-A1
优先权日:2023-04-21
标题 :Methods for preparing (-)-epicatechin
发明人：PAIS GODWIN
权利人:MARS INC
摘要:Methods steps for the synthesis of (-)-epicatechin are provided herein. The synthetic methods are provided in two phases: (1) synthesis of epoxide intermediates and (2) synthesis of (-)-epicatechin.

专利号:US-2024400552-A1
优先权日:2016-11-11
标题 :Heterocyclic modulators of lipid synthesis
发明人：BUCKLEY DOUGLAS I; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
权利人:SAGIMET BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by dysregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

专利号:US-11622968-B2
优先权日:2011-03-08
标 题:Heterocyclic modulators of lipid synthesis
发明人：BUCKLEY DOUGLAS; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
权利人:SAGIMET BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

专利号:US-11034690-B2
优先权日:2016-11-11
标 题:Heterocyclic modulators of lipid synthesis
发明人：BUCKLEY DOUGLAS I; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
权利人:SAGIMET BIOSCIENCES INC; SAGINIET BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).